OrbusNeich will showcase its Genous Stent at TCT 2008, a stent that was CE Marked in 2005. The company’s data suggests that its R Stent has had better outcomes when compared to drug-eluting stents.
Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient’s EPCs reportedly to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.
April 17, 2024 
